Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation

Epilepsia

Volumn 54, Issue 8, 2013, Pages 1444-1452

  Bialer, Meir ^a   Shekh Ahmad, Tawfeeq ^a   Braun, Tricia L ^b   Halvorsen, Mark B ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b Upsher Smith Laboratories Inc   (United States)

Author keywords

Healthy subjects; Pharmacokinetics; Steady state; Topiramate extended release formulation; USL255

Indexed keywords

TOPIRAMATE; UNCLASSIFIED DRUG; USL 255;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD CHEMISTRY; CLINICAL LABORATORY; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CONTUSION; CROSSOVER PROCEDURE; DIARRHEA; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MONITORING; DRUG TOLERABILITY; EXTENDED RELEASE FORMULATION; FEMALE; HEADACHE; HEMATOLOGICAL PARAMETERS; HUMAN; IMMEDIATE RELEASE FORMULATION; MALE; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; NORMAL HUMAN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; POSITIONAL DIZZINESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; VERTIGO; VITAL SIGN;

HEALTHY SUBJECTS; PHARMACOKINETICS; STEADY STATE; TOPIRAMATE EXTENDED-RELEASE FORMULATION; USL255;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTICONVULSANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 84881163836     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12225     Document Type: Article

References (35)

1. Bialer M,. (2007) Extended-release formulations for the treatment of epilepsy. CNS Drugs 21: 765-774.
2. Bialer M, Yacobi A, Moros D, Levitt B, Houle JM, Munsaka MS,. (1998a) Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine. Epilepsia 39: 513-519.
3. Bialer M, Arcavi L, Sussan S, Volosov A, Yacobi A, Moros D, Levitt B, Laor A,. (1998b) Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine. Epilepsy Res 32: 371-378.
4. Bialer M, Doose DR, Murthy B, Curtin C, Wang SS, Twyman RE, Schwabe S,. (2004) Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 43: 763-780.
5. Boxenbaum H, Battle M,. (1995) Effective half-life in clinical pharmacology. J Clin Pharmacol 35: 763-766.
6. Braun TL, Lambrecht LJ, Todd WM, Halvorsen MB,. (2012) Steady-state pharmacokinetic profiles of extended- and immediate-release topiramate [AAN Abstract 6.111]. Presented at the 64th Annual Meeting of the American Academy of Neurology; April 21-28, 2012; New Orleans, LA.
7. Britzi M, Perucca E, Soback S, Levy RH, Fattore C, Crema F, Gatti G, Doose DR, Maryanoff BE, Bialer M,. (2005) Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia 46: 378-384.
8. Caldwell HC, Westlake WJ, Shriver RC, Bumbier EE,. (1981) Steady state lithium blood level fluctuations in man following administration of lithium carbonate conventional and controlled -release dosage form. J Clin Pharmacol 21: 106-109.
9. Chen M-L, Shah VP, Ganes D, MIhha KK, Caro J, Nambiar P, Rocci ML Jr, Avinash GT, Abrahmsson B, Conner D, David B, Fackler P, Farrel C, Gupta S, Katz R, Metha M, Preskorn SH, Sanderink G, Stavchansky S, Temple R, Wang W, Winkle H, Yu L,. (2010) Challenges and opportunities in establishing scientific and regulatory standards for determining therapeutic equivalence of modified-release products: workshop summary report. Clin Ther 32: 1704-1712.
10. Crawford P, Feely M, Guberman A, Kramer G,. (2006) Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 15: 165-176.
11. Doose DR, Streeter AJ,. (2002) Topiramate-chemistry, biotransformation, and pharmacokinetics. In, Levy RH, Mattson RH, Meldrum BS, Perucca E, (Eds) Antiepileptic drugs. 5th ed. Lippincott, Williams & Williams, Philadelphia, PA, pp. 727-734.
12. Doose DR, Walker SA, Gisclon LG, Nayak RK,. (1996) Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol 36: 884-891.
13. Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, Karim RM,. (1996) Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 46: 1684-1690.
14. Garnett WR,. (2000) Clinical pharmacology of topiramate: a review. Epilepsia 41 (Suppl. 1): S61-S65.
15. Gibaldi M, Perrier D,. (1977) Pharmacokinetics. Marcel Dekker, New York, NY, pp. 110-113.
16. Gibaldi M, Perrier D,. (1982) Pharmacokinetics. 2nd ed. Marcel Dekker, New York, NY.
17. Gidal BE,. (2002) Topiramate-drug interactions. In, Levy RH, Mattson RH, Meldrum BS, Perucca E, (Eds) Antiepileptic drugs. 5th ed. Lippincott, Williams & Williams, Philadelphia, PA, pp. 735-739.
18. Girgis IG, Nandy P, Nye JS, Ford L, Mohanty S, Wang S, Ochalski S, Erdekens M, Cox E,. (2010) Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of age. Epilepsia 5: 1954-1962.
19. Janssen Pharmaceuticals, Inc. (2012) Topamax® [Prescribing Information]. Janssen Pharmaceuticals, Inc. Titusville, NJ.
20. Krauss GL, Caffo B, Chang YT, Hendrix CW, Chuang K,. (2011) Assessing bioequivalence of generic antiepilepsy drugs. Ann Neurol 70: 221-228.
21. Kwan KC, Bohidar NR, Hwang SS,. (1984) Estimation of an effective half-life. In, Benet LZ, Levy G, Ferraiolo B, (Eds) Pharmacokinetics: A modern view. Plenum Press, New York, pp. 147-162.
22. Lambrecht LJ, Shekh-Ahmad T, Todd WM, Halvorsen MB, Bialer M,. (2011a) Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. Epilepsia 52: 1877-1883.
23. Lambrecht LJ, Todd WM, Carrithers J, Halvorsen MB,. (2011b) Development and optimization of extended-release formulations of topiramate [AAN abstract 1.116]. Presented at the 63rd Annual Meeting of the American Academy of Neurology; April 9-16, 2011; Honolulu, HI.
24. Lambrecht LJ, Braun TL, Todd WM, Halvorsen MB,. (2012) Switching between immediate- and extended-release formulations does not affect the steady-state pharmacokinetic profile of topiramate [AAN abstract P06.112]. Presented at the 64th Annual Meeting of the American Academy of Neurology; April 21-28, 2012; New Orleans, LA.
25. Maganti L, Panebianco DL, Maes AL,. (2008) Evaluation of methods for estimating time to steady state with examples from Phase 1 studies. AAPS J 10: 141-147.
26. Maryanoff BE, Nortey SO, Gardocki JF, Shank RP, Dodgson SP,. (1987) Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D- fructopyranose sulfamate and related compounds. J Med Chem 30: 880-887.
27. Mimrod D, Specchio LM, Britzi M, Perucca E, Specchio N, La Neve A, Soback S, Levy RH, Gatti G, Doose DR, Maryanoff BE, Bialer M,. (2005) A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. Epilepsia 46: 1046-1054.
28. Pollak PT, Freeman DJ, Carruthers SG,. (1988) Mean apical concentration and duration in the comparative bioavailability of slowly absorbed and eliminated drug preparations. J Pharm Sci 77: 477-480.
29. Privitera M, Fncham R, Penry J, Reife R, Kramer L, Pledger G, Karim R,. (1996) Topiramate placebo-controlled dose ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Neurology 46: 1678-1683.
30. Rowland M, Tozer T,. (2010) Clinical pharmacokinetics and pharmacodynamics. 4th ed. Lippincott, Williams & Williams, Philadelphia, PA.
31. Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, Mather GG, Roskos LK, Shen DD, Thummel KE, Trager WF, Curtin CR, Doose DR, Gisclon LG, Bialer M,. (2002) Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 43: 691-696.
32. Sahin S, Benet LZ,. (2008) The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res 25: 2869-2877.
33. Silber BM, Bialer M, Yacobi A,. (1987) Pharmacokinetic/pharmacodynamic basis of controlled drug delivery. In, Robinson JR, Lee VH, (Eds) Controlled drug delivery. 2nd ed. Marcel Dekker, New York, pp. 213-252.
34. Syed TU, Sajatovic M,. (2010) Extended-release lamotrigine in the treatment of patients with epilepsy. Expert Opin Pharmacother 11: 1579-1585.
35. Yamaoka K, Nakagawa T, Uno T,. (1978) Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6: 547-558.